

Therapy	3TC	dAT	NVP	Req	PN	Est
<input type="checkbox"/> ddi, dAT, NVP	2	2	2	q8h	15	\$33.88
<input type="checkbox"/> ddi, dAT, EFV	5	5	5	q12h	9	\$28.44
<input type="checkbox"/> ddi, NVP, EFV	5	5	5	q8h	16	\$38.50
<input type="checkbox"/> dAT, NVP, EFV	5	5	5	q8h	14	\$40.24
<input type="checkbox"/> ddi, NVP, EFV	5	7	7	q8h	15	\$38.77
<input type="checkbox"/> ddi, dAT, EFV	5	7	7	q8h	8	\$28.71

See More Therapies

Therapy Being Evaluated 3TC, dAT, NVP

Evolution

II THERAPY REJECTED III

This therapy was rejected for the following reason(s) Additional information about the therapy is provided but this therapy is NOT advisable

- Viramune (nevirapine/NVP) Resistance Advisory: According to the last genotype data entered, the patient's virus currently has mutation(s) which is/are associated with resistance to Viramune. FilMauE, Rejection54
- Resistance Advisory: According to the last genotype data entered, the patient's virus currently has the following mutations, M184V [RT]. The genotype test displays evidence of the M184V/M184I mutation which is associated with resistance to 3TC. However, this mutant has increased sensitivity to the antiretroviral activity of AZT and ADV so an AZT/3TC or AZT/ADV combination is still useable. Therefore combinations which contain AZT/3TC and AZT/ADV are shown as therapy options although these therapies have been ranked down +5 in favor of three drug combinations with no resistant mutants, FilMauB, Rejection51
- Efavir and Viramune Resistance Advisory: The patient's last phenotypic assay demonstrates phenotypic resistance to Efavir and Viramune, therefore, therapies containing Efavir and Viramune are not recommended at this time. FilResC, Rejection42

Fig. 128

CAUTION

YELLOW ALERT

CAUTION

• NVPΔ: Drug Interaction Alert: Patient is currently taking rifabutin and there is insufficient data to assess whether dose adjustments are necessary. These drugs

←W3

TPMS +1

WEB

How To

TPMS

TPMS

TPMS

TPMS

TPMS

